Drug Profile
Trimetazidine - Martin Pharmaceuticals
Alternative Names: LIVANTRALatest Information Update: 28 Dec 2021
Price :
$50
*
At a glance
- Originator Martin Pharmaceuticals
- Class Anti-ischaemics; Cytoprotectives; Hepatoprotectants; Ischaemic heart disorder therapies; Piperazines; Small molecules; Vasodilators
- Mechanism of Action Adenosine triphosphatase inhibitors; Calcium channel antagonists; Free radical scavengers; Platelet aggregation inhibitors; Thromboxane synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Liver failure
Most Recent Events
- 28 Dec 2021 No recent reports of development identified for phase-I development in Liver-failure in Austria (PO)
- 28 Dec 2021 No recent reports of development identified for phase-I development in Liver-failure in Belgium (PO)
- 28 Dec 2021 No recent reports of development identified for phase-I development in Liver-failure in France (PO)